Reimbursement Is Neurotech's Biggest Risk with Juan-Pablo Mas

<p>In this episode, your host, Liz Moyles, is joined by Juan-Pablo Mas, Managing Director at Action Potential VC to talk about investing at the frontier of neurotech and bioelectronic medicine, and why reimbursement, not technology, is so often the make-or-break risk.</p><p><br></p><p>Juan-Pablo traces his path from electrical engineering and a formative stint in Medtronic&#39;s cardiovascular division, through Stanford Biodesign and his first venture roles at Morgenthaler and Lightstone, to a decade investing in the brain and nervous system at Action Potential and now the Synapse Fund.</p><p><br></p><p>He explains what he looks for in founders, why &quot;herd mentality&quot; in venture is where the real opportunity hides, how AI and signal processing are reshaping neurotech, and where he sees the healthcare system heading as clinical resources become more abundant.</p><p><br></p><p>Key Topics:</p><p>Juan-Pablo&#39;s route from engineering and Medtronic to venture and the Synapse Fund</p><p>Investing in neuromodulation, bioelectronic medicine and the wider neurotech market</p><p>How AI, signal processing and machine learning are accelerating the field</p><p>What separates fundable founders from the rest</p><p>Why reimbursement is the single biggest risk in neurotech today</p><p><br></p><p>Related Insights:</p><p>The &quot;thirsty learner&quot; founder mindset saying &quot;I don&#39;t know, but I&#39;ll find out&quot;</p><p>Why a unique, against-the-grain take is where returns are made</p><p>Choosing investors and boards who actually understand the business technically</p><p>The shift toward preventative health as an investable category</p><p>Designing healthcare for abundance agentic tools, BCI and what comes next</p><p><br></p><p>Core Challenges:</p><p>Reimbursement and coverage decisions not the technology are often the hardest, riskiest part of bringing a neurotech to market. Agencies can default to denial, and a single coverage setback can hit a company exactly when its burn is highest.</p><p>Founders need a credible reimbursement and commercialisation strategy from day one, and a board that genuinely understands the business otherwise they risk setting up failure at later rounds without realising it.</p><p><br></p><p>🎧 Tune in now to hear why the brain is medtech&#39;s last great frontier and what it really takes to fund and build there.</p><p><br></p><p>The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. </p><p><br></p><p>To learn more about Cruxx,<a href="https://www.thisiscruxx.com/">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a></p><p><br></p><p>A big thank you to our sponsors on this season of the podcast; </p><p><br></p><p><a href="https://www.linkedin.com/company/the-technology-partnership/">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a> With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you&#39;re a startup or a multinational, <a href="https://www.linkedin.com/company/the-technology-partnership/">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a> can accelerate your development with the latest technologies. Learn more at <a href="http://ttp.com/">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a></p><p><br></p><p><br></p>